The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•17 April 2026•

1 min read

COPD Market Set to Reach $11.5 Billion in 2024 Driven by Biological Therapy Advancements

Key Facts

1The COPD market is projected to reach approximately USD 11.5 billion in 2024.

2Major firms including AstraZeneca, GSK, Sanofi, and Regeneron are leading the development of new therapies in Phase III trials.

The Chronic Obstructive Pulmonary Disease (COPD) market is projected to reach approximately $11.5 billion in 2024, with significant expansion forecasted through 2034. Industry giants including AstraZeneca, GSK, Sanofi, and Regeneron are spearheading this growth, with several innovative therapies currently in Phase III clinical trials. This market expansion is primarily driven by an aging global population and rising prevalence rates of respiratory conditions. Furthermore, the industry is witnessing a strategic shift from traditional inhalers toward advanced biological treatments, which is expected to enhance market valuation. Despite hurdles such as high treatment costs, the long-term outlook remains bullish for pharmaceutical firms with robust respiratory pipelines. These developments signal substantial investment opportunities within the healthcare and biotech sectors over the next decade.